)
Hyderabad-based drug maker Aurobindo Pharma Limited reported a 5.7 per cent growth in net profit at Rs 235 crore for the quarter ended September 30, compared with a profit of Rs 222.4 crore a year ago. Operating income during the period increased 27.6 per cent to Rs 1913.9 crore from Rs 1500.4 crore.
Aurobindo’s managing director, N Govindarajan, stated the integrated business in generic formulations was auguring well to drive the operating performance.
“We are also investing in specific new, differentiated products offerings such as oncology, hormones, peptides and OTC (over the counter) business, which we believe will complement our business in the coming years,” he said commenting on the company’s future plans.
During the second quarter of the current financial year, formulations constituted 63.1 per cent of the gross sales, while the remaining 36.9 per cent of the sales turnover came from active pharmaceutical ingredients.
Earnings per share during the quarter stood at Rs 8.07 and it declared an interim dividend of 125 per cent amounting to Rs 1.25 per equity share.
The company’s scrip closed on the BSE at Rs 260.45, up 9.27 per cent, over the previous day’s close of Rs 238.35.
